Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma

Pediatric Blood and Cancer

Volumn 59, Issue 7, 2012, Pages 1190-1197

  Saarinen Pihkala, Ulla M ^a   Hovi, Liisa ^a   Koivusalo, Antti ^a   Jahnukainen, Kirsi ^a   Karikoski, Riitta ^a   Sariola, Hannu ^a   Wikström, Sakari ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplantation; High dose therapy; High risk neuroblastoma; Tandem high dose therapy; Triple high dose therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FERRITIN; HOMOVANILLIC ACID; MELPHALAN; NEURON SPECIFIC ENOLASE; TENIPOSIDE; THIOTEPA; VANILMANDELIC ACID; VINCRISTINE;

ABDOMINAL RADIOGRAPHY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BONE SCINTISCANNING; BRAIN RADIATION; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENGRAFTMENT; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; INFANT; KIDNEY FAILURE; LONG TERM CARE; MALE; MULTIPLE ORGAN FAILURE; MYCOSIS; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SCHOOL CHILD; SEPTICEMIA; SINGLE DRUG DOSE; SOUTHERN BLOTTING; THORAX RADIOGRAPHY; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; MELPHALAN; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84867343512     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24173     Document Type: Article

References (36)

1. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 2008; 41: 159- 165.
2. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: The US experience. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA, editors. Neuroblastoma. New York: Elsevier Science B.V; 2000. pp. 417- 436.
3. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050- 1058.
4. Kretschmar CS, Kletzel M, Murray K, et al. Response to palitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: A Pediatric Oncology Group study. J Clin Oncol 2004; 22: 4119- 4126.
5. Pradhan KR, Johnson CS, Vik TA, et al. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer 2006; 46: 793- 802.
6. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165- 1173.
7. Berthold F, Boos J, Burdach S. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients wit. high-risk neuroblastoma: A randomized controlled trial. Lancet Oncol 2005; 9: 649- 658.
8. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumor Working Party. Eur J Cancer 1997; 12: 2130- 2135.
9. Ladenstein R, Philip T, Lasset O, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953- 965.
10. Kaneko M, Tsuchida Y, Uchino J, et al. Treatment results of advanced neuroblastoma with the First Japanese Study Group Protocol. J Pediatr Hematol Oncol 1999; 21: 190- 197.
11. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468- 476.
12. Castel V, Caňete A, Navarro S, et al. Outcome of high-risk neuroblastoma using a dose intensity approach: Improvement in initial but not long-term results. Med Pediatr Oncol 2001; 37: 537- 542.
13. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592- 1601.
14. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomized trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005; 44: 348- 357.
15. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007- 1013.
16. Ladenstein RL. Busulfan-Melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. 2011 ASCO Annual Meeting Proceedings (abstract #2).
17. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Br J Cancer 1993; 67: 119- 127.
18. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18: 2567- 2575.
19. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24: 2891- 2896.
20. Qayed M, Chiang KY, Ricketts R, et al. Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma. Pediatr Blood Cancer 2012; 58: 448- 452.
21. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study. J Clin Oncol 2002; 20: 2284- 2292.
22. 123I-Metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22: 3909- 3915.
23. Yu AL, Gilman AL, Ozkaynak F, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324- 1334.
24. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466- 1477.
25. Pearson ADJ, Philip T. Prognosis of low-risk and high-risk neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA, editors. Neuroblastoma. New York: Elsevier Science B.V. 2000. pp. 551- 560.
26. Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2008; 27: 289- 297.
27. Saarinen UM, Wikström S, Mäkipernaa A, et al. In vivo purging of bone marrow in children with poor risk neuroblastoma for marrow collection and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 2791- 2802.
28. Cheung N-KV, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45: 2642- 2649.
29. Cheung N-KV, von Hoff DD, Strandjord SE, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986; 4: 363- 369.
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457- 481.
31. Peto R, Pike MC, Armitage P. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and experience. Br J Cancer 1977; 35: 1- 39.
32. Moroz V, Machin D, Faldum A. et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International neuroblastoma Risk Group Project. Eur J Cancer 2011; 47: 561- 571.
33. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486- 2493.
34. Broniscer A, Nicolaides TP, Dunkel IJ, et al. High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatr Blood Cancer 2004; 42: 261- 267.
35. Butturini AM, Jacob M, Aguajo J, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Cancer 2009; 115: 2956- 2963.
36. Dunkel IJ, Gardner SL, Garvin JH, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. J Neurooncol 2010; 12: 297- 303.